|
Physicians' Clinical Support System-Buprenorphine (PCSS-B), a collaborative effort between the American Academy of Addiction Psychiatry, American Academy of Osteopathic Addiction Medicine, and American Psychiatric Association continues to make great progress in training, mentoring and providing resources for physicians who treat patients with opioid dependence. The number of trained physicians continues to grow each year. We hope you find our resources helpful. Your feedback is greatly appreciated!
Hot Topic Webinar: March 12, 2013 (12:00-1:00 pm ET)
Title: Pain Management in Patients on Buprenorphine Maintenance
Presenter: Daniel P. Alford, MD, MPH, FACP, FASAM, Associate Professor of Medicine
Boston University School of Medicine, Medical Director, Office-Based Opioid Treatment Program
To Register: Click here
Our Archived Webinars are great informational resources as well. This month's spotlight webinar is:
Title: Medical Co-morbidities
Presenter: David Fiellin, MD and Jeanette Tetrault, MD
To View this webinar click here.
Looking for a full list of educational activities for the PCSS-B and PCSS-O projects? Click here.
Upcoming Half and Half Webinars: Waiver Eligibility Training
Date: Wednesday, February 27, 2013
Course Director: William Morrone, DO
Time: 5:00 pm – 9:30 pm PT
Click Here to Register!
Date: Saturday, March 9, 2013
Course Director: Stephen Wyatt, DO
Time: 8:00 am - 12:30 pm ET
Click Here to Register!
The PCSS-B website offers a variety of resources, from Clinical Tools, Clinical Guidances, and news articles to information on upcoming trainings. Visit the website at: www.pcssb.org.
Addiction Psychiatry Council Chair John Renner, MD, discusses buprenorphine treatment training, click here to view the video.
Funding for this training was made possible (in part) by contract#1H79T1022022 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
|
